CONTE, PIERFRANCO
CONTE, PIERFRANCO
0.1 grams of sub-cutaneous adipose tissue (SCAT) as source of adult multipotent mesenchymal stromal cells (MSC) for cell-based therapies.
2007 Dominici, M; Sternieri, R; De Fazio, D; Cafarelli, L; Guaraldi, G; Spano, C; Rasini, V; Paolucci, P; Cilli, M; Piccardi, F; Astori, G; Hofmann, Tj; Horwitz, Em; Conte, Pierfranco
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts)
2021 Dal Maso, A.; Pavan, A.; Ferro, A.; Pretelli, G.; Frega, S.; Menis, J.; Pasello, G.; Guarneri, V.; Conte, P. F.; Bonanno, L.
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI)
2020 Dal Maso, A.; Ferro, A.; Lorenzi, M.; Polo, V.; Scattolin, D.; Del Conte, A.; Scoccia, E.; Frega, S.; Bonanno, L.; Indraccolo, S.; Calabrese, F.; Guarneri, V.; Conte, P. F.; Pasello, G.
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)
2021 Lorenzi, M.; Dal Maso, A.; Ferro, A.; Polo, V.; Scattolin, D.; Macerelli, M.; Follador, A.; Targato, G.; Indraccolo, S.; Frega, S.; Menis, J.; Bonanno, L.; Guarneri, V.; Conte, P. F.; Pasello, G.
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series
2016 Pasello, G; Polo, V; Frega, Stefano; Lorenzi, M; Indraccolo, S; Fassan, Matteo; Bonanno, L; Nannini, N; Conte, Pierfranco; Calabrese, Fiorella
186O Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial
2018 Dieci, MARIA VITTORIA; Conte, Pierfranco; Bisagni, G; A Brandes, A; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Omarini, C; Maiorana, A; Orvieto, E; Sanders, M; D'Amico, R; Guarneri, Valentina
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis
2016 Evangelista, Laura; Dieci, MARIA VITTORIA; Guarneri, Valentina; Conte, Pierfranco
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis
2016 Urso, L; Polo, V; Bonanno, L; Nannini, N; Lunardi, F; Vuljan, S. E; Conte, P. F; Rea, Federico; Calabrese, Fiorella
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS)
2016 Bonanno, L.; Schiavon, Marco; Lunardi, Francesca; Tebaldi, M.; Calistri, D.; Pasello, Giulia; Conte, Pierfranco; Rea, Federico; Indraccolo, Stefano; Calabrese, Fiorella
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
1987 M., Bruzzone; S., Chiara; A., Falcone; G., Graziani; Conte, Pierfranco; R., Rosso
5-fluorouracil administered as a 48-hour semi-intermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients
2004 Allegrini, G; Falcone, A; DI MARSICO, R; Lencioni, M; Masi, G; Galli, C; Cupini, S; Pfanner, E; Marcucci, L; Conte, Pierfranco
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial
2016 Del Mastro, Lucia; Levaggi, Alessia; Michelotti, Andrea; Cavazzini, Giovanna; Adami, Francesca; Scotto, Tiziana; Piras, Margherita; Danese, Saverio; Garrone, Ornella; Durando, Antonio; Accortanzo, Valeria; Bighin, Claudia; Miglietta, Loredana; Pastorino, Simona; Pronzato, Paolo; Castiglione, Federico; Landucci, Elisabetta; Conte, Pierfranco; Bruzzi, Paolo
5-Fluoruracil administered as a 48-hours chronomodulated infusion in combination with Leucovorin and Cisplatin: a randomized phase II study in metastatic colorectal cancer.
2001 A., Falcone; G., Allegrini; G. L., Masi; M., Lencioni; E., Pfanner; I., Brunetti; R., Danesi; G., Bocci; M., Del Tacca; Conte, Pierfranco
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features
2021 Bonanno, L.; Dal Maso, A.; Pavan, A.; Zulato, E.; Esposito, G.; Fassan, M.; Nardo, G.; Pasello, G.; Guarneri, V.; Calabrese, F.; Rea, F.; Indraccolo, S.; Conte, P. F.
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC)
2016 Bonanno, L; Calabrese, Fiorella; De Paoli, A; Pasello, G; Santo, A; Favaretto, A; Chilosi, M; Del Conte, A; Conte, P. F; Indraccolo, S.
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
2018 Conte, P; Frassoldati, A; Bisagni, G; Brandes, A A; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A; Pronzato, P; Giovanardi, F; Moretti, G; Lombardo, L; Schirone, A; Beano, A; Amaducci, L; Bajardi, E A; Vicini, R; Balduzzi, S; D'Amico, R; Guarneri, V
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER.
2010 Guarneri, V; Frassoldati, A; Gebbia, V; Bisagni, G; Cavanna, L; Donadio, M; Lelli, G; Musolino, A; Colucci, G; Banna, Gl; Degli Esposti, R; Ferro, A; Grasso, F; Zamagni, C; Amadori, D; Aieta, M; Molino, A; Garrone, O; Aitini, E; Fornari, G; Cascinu, S; Rossi, G; D'Amico, R; Conte, Pierfranco
[Adjuvant chemotherapy in breast cancer. International perspective]
2000 Conte, P F; Gennari, A
[Experimentation with Di Bella polychemotherapy in Tuscany].
2000 C., Orlandini; G., Amunni; Conte, Pierfranco; G., Francini; G. C., Rossini; D., Vanni; G. d., Riferimento
[Targeted therapy in non-small cell lung tumors: recent findings and future perspectives]
2005 Conte, P F; Barbieri, F